[采用N(4)-山嵛酰-1-β-D-阿拉伯呋喃糖基胞嘧啶、阿克拉霉素、6-巯基嘌呤及泼尼松龙联合化疗（BH-AC. AMP疗法）治疗成人急性非淋巴细胞白血病]
[Combination chemotherapy of N(4)-behenoyl-1-beta-arabinofuranosylcytosine, aclarubicin, 6-MP, and prednisolone (BH-AC. AMP therapy) for adult acute non-lymphocytic leukemia].
作者信息
Ishige K, Takagi T, Oguro M
出版信息
Gan To Kagaku Ryoho. 1984 Jul;11(7):1475-9.
Sixteen of 20 patients(80%) with adult ANLL treated with B H-AC X AMP therapy attained complete remission (CR). According to the FAB classification, CR rate was 6 out of 8 (75%) for M1, 3 out of 5 (60%) for M2, 2 out of 2 (100%) for M3, and 5 out of 5 (100%) for M4. The median of remission duration in 16 patients who attained CR was 8 months and appeared to be longer in patients with M2, rather than other types, of leukemia than in those with the other types of leukemia. BH-AC X AMP therapy is highly effective for remission induction in adult ANLL and long term disease free survival could be expected by addition of appropriate maintenance therapy.
接受BH-AC X AMP疗法治疗的20例成年急性非淋巴细胞白血病（ANLL）患者中有16例（80%）获得完全缓解（CR）。根据FAB分类，M1型8例中有6例（75%）达到CR，M2型5例中有3例（60%），M3型2例中有2例（100%），M4型5例中有5例（100%）。16例获得CR的患者缓解期的中位数为8个月，M2型白血病患者的缓解期似乎比其他类型白血病患者的更长。BH-AC X AMP疗法在诱导成年ANLL缓解方面非常有效，通过添加适当的维持治疗有望实现长期无病生存。
Zotero 插件